Crohns & Colitis Foundation

Our Impact

The Crohn's & Colitis Foundation has been at the forefront of inflammatory bowel disease research and care for more than 50 years and counting. We invest in IBD research, education, support, and advocacy initiatives.

We won't stop until we achieve our vision — a future free from Crohn's disease and ulcerative colitis.

Striving to Find a Cure for Crohn's Disease and Ulcerative Colitis

The Foundation is one of the largest sources of funding for IBD research. We have invested more than $350 million into finding the causes, treatments, and cures for Crohn's disease and ulcerative colitis.

We have played a role in every major IBD research breakthrough, including:

• The importance of TNF-alpha and its role in IBD. Antibodies to this immune system chemical led to a number of groundbreaking biologic therapies, including infliximab (Remicade) and adalimumab (Humira)
• The discovery of NOD2, the first gene identified as relevant for Crohn's disease
• The discovery of the link between IL-23 and IBD, which led to the discovery and approval of ustekinumab (Stelara)